Novel Precision Medicine approach in women’s pregnancy health
Our Mission
Treating with a best-in-class therapeutic to both extend gestation and improve neonate outcomes.
Meet our executive team
Philippe Douville, PhD, MBA
Chief Executive Officer
• Accomplished biotech entrepreneur
• +20 years industry experience in senior executive roles
• Founder of Milestone Pharmaceuticals (NASDAQ: MIST)
• ~$250 M in equity financing
Jean-Pierre Moreau
Head of Preclinical Development
• Recognized expert in non-clinical PK, pharmacology, and toxicology
• +30 years industry experience
Managerial responsibility in preclinical therapeutic development of CROs and biopharmaceutical companies (CiToxLAB, Mispro, MDS, Bio-Research, Biopharmacopae
Dag Richter, MSc, MBA
Corporate Business Advisor
• Chairman of General Partnerships of HealthCap Venture Capital fund VI, VII and VIII.
• > 25 completed investment transactions leading to 8 IPOs and several corporate deals.
• Involved in medical device markets and technologies since 1995
• MSc in materials science from KTH Stockholm and an MBA from IMD Lausanne.
Michael C LIttle, PhD
Chief Operation Officer
• Seasoned pharma diagnostics executive
• >30 years industry experience
• Executive leadership positions
- Novartis Pharmaceuticals VP & Global Head Companion Dx
- Novartis Diagnostics VP & Global Head R&D, Medical &
Regulatory Affairs
- BD Diagnostics, Worldwide Business Leader, MDx
The founders
Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS
Founder and Scientific Officer – Therapeutics
• Reputed neonatologist and pharmacologist, with expertise on mechanisms involving inflammation and preterm labor
• Professor of Pediatrics, and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University
• His seminal work also triggered the approval (EMEA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus
• >250 articles and inventor in 25 patents
• Member of the Canadian Academy of Health Sciences
• Canada Research Chair: Leopoldine Wolfe Chair in Translational Research
David Olson, PhD
Founder and Scientific Officer – Diagnostics
• Professor Medicine & Dentistry, Obstetrics and Gynecology, UofA
• Founding director or co-director of the University of Alberta Perinatal Research Centre, the CIHR Group in Perinatal Health and Disease, AIHS Interdisciplinary Preterm Birth and Healthy Outcomes Team
Christiane Quiniou, PhD, MBA
Founder and Director of Research
• PhD in Biochemistry and EMBA in Technology Management
• Protein structure specialist with many years of experience in conception and characterization of allosteric modulators
• > 25 publications and inventor in 10 patents
Dag Richter, MSc, MBA
Corporate Business Advisor
• Chairman of General Partnerships of HealthCap Venture Capital fund VI, VII and VIII.
• > 25 completed investment transactions leading to 8 IPOs and several corporate deals.
• Involved in medical device markets and technologies since 1995
• MSc in materials science from KTH Stockholm and an MBA from IMD Lausanne.